Llinàs-Brunet M, Bailey M, Déziel R, Fazal G, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart M A, Rancourt J, Thibeault D, Wernic D, Lamarre D
Boehringer Ingelheim (Canada) Ltd, Bio-Méga Research Division, Laval, Québec, Canada.
Bioorg Med Chem Lett. 1998 Oct 6;8(19):2719-24. doi: 10.1016/s0960-894x(98)00480-6.
Replacement of the C-terminal carboxylic acid functionality of peptide inhibitors of hepatitis C virus (HCV) NS3 protease (complexed with NS4A peptide cofactor) by activated carbonyl groups does not produce any substantial increase in potency. These latter inhibitors also inhibit a variety of other serine and cysteine proteases whereas the carboxylic acids are specific. Norvaline was identified as a chemically stable replacement for the P1 residue of Ac-DDIVPC-OH which was also compatible with activated carbonyl functionalities.
用活化羰基取代丙型肝炎病毒(HCV)NS3蛋白酶(与NS4A肽辅因子复合)的肽抑制剂的C端羧酸官能团,不会使效力有任何显著提高。这些后一种抑制剂还抑制多种其他丝氨酸和半胱氨酸蛋白酶,而羧酸类则具有特异性。正缬氨酸被确定为Ac-DDIVPC-OH的P1残基的化学稳定替代物,它也与活化羰基官能团兼容。